Last reviewed · How we verify

NCT03923335

The Predictive Value of Guangzhou Panel for Recurrence in Early-stage Colorectal Cancer

Not yet recruiting Last updated 22 April 2019
What this trial tests

trial testing DNA methylation detection in Colorectal Neoplasms in 287 participants. Not yet recruiting.

Timeline
30 April 2019
Primary endpoint
30 April 2021
31 December 2026

Quick facts

Lead sponsorSixth Affiliated Hospital, Sun Yat-sen University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment287
Start date30 April 2019
Primary completion30 April 2021
Estimated completion31 December 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University

Who can join

Adults 40 to 70, any sex, with Colorectal Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the predictive value of a four-gene methylation assay called Guangzhou Panel in early-stage colorectal cancer. Patients will be divided into two groups: high risk group and low risk group. The primary endpoint is 5 year disease free survival (DFS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Colorectal Neoplasms

Currently open trials in the same condition.

Other Sixth Affiliated Hospital, Sun Yat-sen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03923335.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing